Rahway, New Jersey, USA--Merck (NYSE: MRK),announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® as an adjunct to reduce low-density lipoprotein cholesterol (LDL-C) setting the world record for being the First Oral PCSK9 Inhibitor to Lower LDL Cholesterol, according to the WORLD RECORD ACADEMY.